Difference between revisions of "Bosutinib (Bosulif)"
Jump to navigation
Jump to search
(Created page with "==General information== Class/mechanism: Third-generation tyrosine kinase inhibitor, targets Abl and Src kinases. Active against many imatinib-resistant mutations, but is not ac...") |
|||
| Line 6: | Line 6: | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert. | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert. | ||
==Patient drug information== | ==Patient drug information== | ||
| − | + | No information available. | |
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 03:04, 24 December 2011
General information
Class/mechanism: Third-generation tyrosine kinase inhibitor, targets Abl and Src kinases. Active against many imatinib-resistant mutations, but is not active against the T315I mutation.[1][2]
Route: Oral
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert.
Patient drug information
No information available.